#100000
I came here to work <a href=" http://weimar.edu/finance-assignment-helper/ ">custom written</a> REGARD is a global, randomized, double-blind trial of ramucirumab and best supportive care compared to placebo and best supportive care as treatment in 355 patients with advanced gastric cancer, including adenocarcinomas of the gastro-esophageal junction following progression after initial chemotherapy.
Submitted by Anonymous (not verified) on Fri, 10/31/2014 - 09:43 to Technology |
